Evolus (EOLS) Q2 FY26 earnings call

Evolus delivered a strong second quarter, marked by significant revenue growth and sustained profitability, leading to a raised full-year outlook. The company expanded its portfolio with strategic licensing agreements for Profilo and Cimetase, diversifying into skin quality and broadening its international footprint. Management highlighted market share gains in the US injectable aesthetics market and the increasing traction of its portfolio strategy.